U.S. approval of an expanded indication for transcatheter aortic valve replacement in patients without symptoms is among the ...

View all available purchase options and get full access to this article.

Anteris Technologies today announced the launch of its initial public offering in the U.S. to advance the development of its ...

The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results ...

The US transcatheter heart valve market, and specifically the transcatheter aortic valve replacement segment, is one that has been well-researched and is well-known. The growth that has been seen ...

On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

Ahmedabad Meril Life Sciences, a leading global med-tech company, launched the Myval Octapro Transcatheter Heart Valve (THV) ...